Relmada Therapeutics Q4 EPS $(0.84) Misses $(0.83) Estimate
Portfolio Pulse from Happy Mohamed
Relmada Therapeutics reported a Q4 EPS loss of $(0.84), missing the consensus estimate of $(0.83) by 1.2%. This represents a 34.38% improvement over the $(1.28) per share loss from the same period last year.
March 19, 2024 | 8:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Relmada Therapeutics reported a Q4 EPS loss of $(0.84), missing estimates by 1.2% but improved 34.38% YOY.
The slight miss in EPS estimates may cause short-term negative sentiment, but the significant year-over-year improvement indicates a positive trend in reducing losses, which could mitigate any negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100